Logo
x

Search

Subscribe Now

Scynexis

SCYNEXIS and Hansoh Pharma Report the NMPA Acceptance of NDA for Ibrexafungerp to Treat Adult and Post-Menarchal Pediatric Females with Vulvovaginal Candidiasis

SCYNEXIS and Hansoh Pharma Report the NMPA Acceptance of NDA for Ibrexafungerp to Treat Adult and Post-Menarchal Pediatric Females...

  • July 21, 2023
Insights+: The US FDA New Drug Approvals in December 2022

Insights+: The US FDA New Drug Approvals in December 2022

  • January 18, 2023
SCYNEXIS’ Brexafemme (ibrexafungerp) Receives the US FDA’s Approval for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

SCYNEXIS’ Brexafemme (ibrexafungerp) Receives the US FDA’s Approval for Reduction in Incidence of Recurrent Vulvovaginal Candidias...

  • December 2, 2022
Scynexis Presents P-III (CANDLE) Study Results of Ibrexafungerp for the Prevention of Recurrent Vaginal Yeast Infections at IDSOG 2022

Scynexis Presents P-III (CANDLE) Study Results of Ibrexafungerp for the Prevention of Recurrent Vaginal Yeast Infections at IDSOG...

  • August 5, 2022
Scynexis Reports Interim Results of Ibrexafungerp in P-III (FURI) and (CARES) Studies for the Treatment of Severe Fungal Infections

Scynexis Reports Interim Results of Ibrexafungerp in P-III (FURI) and (CARES) Studies for the Treatment of Severe Fungal Infection...

  • April 25, 2022
Scynexis Reports Results of Ibrexafungerp in P-III (CANDLE) Study for the Prevention of Recurrent Vaginal Yeast Infections

Scynexis Reports Results of Ibrexafungerp in P-III (CANDLE) Study for the Prevention of Recurrent Vaginal Yeast Infections

  • February 11, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.